Fineline Cube

Follow:
14486 Articles
Samsung Bioepis and Teva Partner on Biosimilar EPYLLI for US Market
CompanyDeals

Samsung Bioepis and Teva Partner on Biosimilar EPYLLI for US Market

Sepax Technologies Debuts on STAR Market with Soaring IPO Prices
CompanyDeals

Sepax Technologies Debuts on STAR Market with Soaring IPO Prices

Bayer Files for Finerenone Approval in US and China for Heart Failure
CompanyDrug

Bayer Files for Finerenone Approval in US and China for Heart Failure-Fineline Info & Tech

Pfizer's Sasanlimab Shows Positive Results in Phase III CREST Study
CompanyDrug

Pfizer’s Sasanlimab Shows Positive Results in Phase III CREST Study

NMPA Approves J&J's FGFR Kinase Inhibitor Balversa for Urothelial Carcinoma
CompanyDrug

NMPA Approves J&J’s FGFR Kinase Inhibitor Balversa for Urothelial Carcinoma

Doma Biopharma Receives FDA Clearance for DM002 Phase I Study
CompanyDrug

Doma Biopharma Receives FDA Clearance for DM002 Phase I Study-Fineline Info & Tech

GSK's Shingrix Prefilled Syringe Accepted for FDA Review
CompanyDrug

GSK’s Shingrix Prefilled Syringe Accepted for FDA Review

NHSA Launches Nationwide Self-Inspection Campaign on Medical Insurance Fund Usage
Policy / Regulatory

NHSA Launches Nationwide Self-Inspection Campaign on Medical Insurance Fund Usage

China's NHSA Implements New Regulations for Medical Insurance Payment Qualifications
Policy / Regulatory

China’s NHSA Implements New Regulations for Medical Insurance Payment Qualifications

Shenzhen Oculgen Secures Over RMB 100 Million in Series A Funding
Company

Shenzhen Oculgen Secures Over RMB 100 Million in Series A Funding

Fosun Pharmaceutical's FCN-437c Accepted for NMPA Review for Breast Cancer Treatment
CompanyDrug

Fosun Pharmaceutical’s FCN-437c Accepted for NMPA Review for Breast Cancer Treatment

Hengrui's SHR4640 Accepted for NMPA Review for Gout and Hyperuricemia Treatment
CompanyDrug

Hengrui’s SHR4640 Accepted for NMPA Review for Gout and Hyperuricemia Treatment